2001 November
Natural killer cell‐based immunotherapy in cancer: current insights and future prospects.
As our understanding of the molecular mechanisms governing natural killer (NK) cell activity increases, their potential in cancer immunotherapy is growing increasingly prominent.
2001 November
The biology of human natural killer-
cell subsets.
Human natural killer (NK) cells comprise ≈15% of all circulating lymphocytes.
2001 November
A central role for death
receptor-mediated apoptosis
in the rejection of tumors
by NK cells.
NK cells provide a line of defense against tumors and virus-infected cells that have lost the expression of one or more MHC class I isoforms.
2001 November
Natural killer cell‐based immunotherapy in cancer: current insights and future prospects.
As our understanding of the molecular mechanisms governing natural killer (NK) cell activity increases, their potential in cancer immunotherapy is growing increasingly prominent.
2001 November
A critical role for natural killer cells in dendritic cell-based anticancer immunotherapy.
Multipronged immunotherapies that activate both T cells and natural killer (NK) cells may result in more robust and durable anticancer responses.
2006 May
Genetically re-engineered K562 cells significantly expand and functionally
activate cord blood natural killer cells:
Potential for adoptive cellular immunotherapy.
Natural killer (NK) cells play a significant role in reducing relapse in patients with hematological malignancies after allogeneic stem cell transplantation, but NK cell number and naturally occurring inhibitory signals limit their capability.
2008 May
Correlation between NK function and response to trastuzumab in metastatic
breast cancer patients
Trastuzumab is a monoclonal antibody selectively directed against Her2 and approved for the treatment of Her2 overexpressing breast cancer patients.
2008 June
Umbilical cord blood transplantation: basic biology
and clinical challenges to immune reconstitution.
Allogeneic stem cell transplantation has continued to evolve as a common procedure for the treatment of hematological malignancies and bone marrow failure.
2008 July
CD16+ CD56- NK cells in the peripheral
blood of cord blood transplant recipients:
a unique subset of NK cells possibly
associated with graft-versus-leukemia
effect.
A marked increase in CD16+ CD56- NK cells in the peripheral blood (PB) was observed in a cord blood transplant (CBT) recipient with refractory acute myeloid leukaemia (AML) in association with attaining molecular remission.
2009 April
Fully functional NK cells after unrelated
cord blood transplantation.
Promising results of umbilical cord blood transplantation (UCBT) from unrelated donors have been reported in patients with hematologic disorders.
2013 January
GMP-Compliant, Large-Scale Expanded Allogeneic Natural Killer Cells Have Potent Cytolytic Activity against Cancer Cells
In Vitro and In Vivo
Ex vivo-expanded, allogeneic natural killer (NK) cells can be used for the treatment of various types of cancer.
2012 July
Generation of natural killer cells from hematopoietic stem cells in vitro for immunotherapy.
Natural killer (NK) cells are part of the innate immune system and are an alluring option for immunotherapy due to their ability to kill infected cells or cancer cells without prior sensitization.
2013 November
Reduction of the CD16−CD56 bright NK
Cell Subset Precedes NK Cell Dysfunction
in Prostate Cancer
Natural cytotoxicity, mediated by natural killer (NK) cells plays an important role in the inhibition and elimination of malignant tumor cells.
2014 June
Positive and negative regulation by
NK cells in cancer.
Our understanding of NK biology has expanded immensely since the initial discovery of natural killer cells in 1975.
2015 November
Advances in clinical NK cell studies:
Donor selection, manufacturing and
quality control.
Natural killer (NK) cells are increasingly used in clinical studies in order to treat patients with various malignancies.
2016 January
Cord Blood as a Source of Natural Killer
Cells
ord blood (CB) offers several unique advantages as a graft source for hematopoietic stem cell transplantation (HSCT).
2016 November
Manufacturing Natural Killer Cells as Medicinal Products.
Natural Killer (NK) cells are innate lymphoid cells (ILC) with cytotoxic and regulatory properties.
2017 February
Genetically re-engineered K562 cells significantly expand and functionally
activate cord blood natural killer cells:
Potential for adoptive cellular
immunotherapy
Natural killer (NK) cells play a significant role in reducing relapse in patients with hematological malignancies after allogeneic stem cell transplantation, but NK cell number and naturally occurring inhibitory signals limit their capability.
2017 March
Umbilical Cord Blood Natural Killer Cells,
Their Characteristics, and Potential
Clinical Applications.
Natural killer (NK) cells are lymphocytes of the innate immune system able to kill different targets such as cancer cells and virally infected cells without prior activation making then attractive candidates for cancer immunotherapy.
2017 April
Shaping of Natural Killer Cell
Antitumor Activity by Ex Vivo Cultivation.
Natural killer (NK) cells are a promising tool for the use in adoptive immunotherapy, since they efficiently recognize and kill tumor cells.
2017 May
Characterization of cord blood natural
killer cells: implications for transplantation
and neonatal infections.
The role of natural killer (NK) cells in hematopoietic stem cell transplantation and in the control of neonatal infections is not yet clear. Donor-versus-recipient NK cell alloreactivity was found to improve outcome in some settings of hematopoietic stem cell transplantation.
2017 May
Fully automated expansion and
activation of clinical-grade natural killer
cells for adoptive immunotherapy.
The role of natural killer (NK) cells in hematopoietic stem cell transplantation and in the control of neonatal infections is not yet clear.
2017 May
Leveraging natural killer cells
for cancer immunotherapy.
Natural killer (NK) cells are potent antitumor effector cells of the innate immune system.
2017 July
Natural Killer Cell-Based Cancer Immunotherapies: From Immune Evasion
to Promising Targeted Cellular
Therapies.
Immunotherapies based on natural killer (NK) cells are among the most promising therapies under development for the treatment of so far incurable forms of leukemia and other types of cancer.
2017 August
NK cell-based cancer immunotherapy:
from basic biology to clinical
application.
atural killer (NK) cells, which recognize and kill target cells independent of antigen specificity and major histocompatibility complex (MHC) matching, play pivotal roles in immune defence against tumors. However, tumor cells often acquire the ability to escape NK cell-mediated immune surveillance.
2017 April
Shaping of Natural Killer Cell Anti -
tumor Activity by Ex Vivo Cultivation
Natural killer (NK) cells are a promising tool for the use in adoptive immunotherapy, since they efficiently recognize and kill tumor cells.
2018 Febuary
Anticancer cellular immunotherapies
derived from umbilical cord blood.
he lack of highly effective drugs in many malignancies has prompted scientific interest in the development of alternative treatment strategies.
2018 February
Cord blood NK cells engineered to express
IL-15 and a CD19-targeted CAR
show long-term persistence and potent
antitumor activity.
Chimeric antigen receptors (CARs) have been used to redirect the specificity of autologous T cells against leukemia and lymphoma with promising clinical results.
2018 April
Ex vivo expansion of human
peripheral blood natural killer cells
and cytotoxic T lymphocytes from
lung cancer patients.
Lung cancer is the most common type of cancer with the highest cancer-associated mortality rates worldwide, as well as in Vietnam.
2018 April
Natural killer-dendritic cell cross-
talk in cancer immunotherapy.
Natural killer (NK) cells and dendritic cells (DCs), two important components of the immune system, can exchange bidirectional activating signals in a positive feedback.
2018 October
Antigen presenting cell-mediated
expansion of human umbilical cord blood yields
log-scale expansion of natural killer
cells with anti-myeloma activity.
Natural killer (NK) cells are important mediators of anti-tumor immunity and are active against several hematologic malignancies, including multiple myeloma (MM).
2018 December
Anti-CD137 monoclonal antibody enhances trastuzumab-induced, natural killer cell-mediated cytotoxicity against pancreatic cancer cell lines with low human epidermal growth factor-like receptor 2 expression.
Because human epidermal growth factor-like receptor (HER) 2 is expressed on the surface of human pancreatic carcinoma cells to varying degrees, trastuzumab, an anti-HER2 monoclonal antibody (mAb), is expected to exert antibody-dependent, natural killer (NK) cell-mediated cytotoxicity (ADCC) against the cells.